Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07856251

Lidocaine Infusions for Pain in Patients With Malignant Bowel Obstruction

Sponsor: Fundación Santa Fe de Bogota

View on ClinicalTrials.gov

Summary

Malignant bowel obstruction is a frequent complication of advanced cancer, particularly of abdominal and pelvic origin, and most affected patients experience pain. Opioids are the mainstay of analgesic treatment, but some patients have pain that does not respond adequately or cannot tolerate further opioid dose increases. Lidocaine infusions are sometimes used as an adjuvant pain treatment in this setting, but specific evidence is limited to case reports and small series. This retrospective cohort study will review the medical records of adults with cancer and malignant bowel obstruction who received lidocaine infusions for pain as part of routine palliative care at Hospital Universitario Fundación Santa Fe de Bogotá (Bogotá, Colombia) between 2015 and 2025. The study will describe patient characteristics and lidocaine regimens, and will evaluate changes in pain intensity and opioid requirements before and after the start of the infusion, the proportion of patients with a clinically meaningful pain reduction, adverse events, treatment discontinuation due to toxicity, and hospital outcomes. The investigators will not assign or modify any treatment.

Official title: Use of Lidocaine Infusions for Pain Management in Patients With Malignant Bowel Obstruction at Hospital Universitario Fundación Santa Fe de Bogotá: A Retrospective Cohort Study

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

OBSERVATIONAL

Enrollment

50

Start Date

2026-11-01

Completion Date

2027-02-01

Last Updated

2026-10-02

Healthy Volunteers

No

Interventions

DRUG

Lidocaine

Continuous intravenous or subcutaneous lidocaine infusion administered with analgesic intent as adjuvant pain treatment in routine clinical practice, with dose, route and duration determined by the treating team. The study does not assign or modify treatment; exposure data are abstracted retrospectively from medical records.